U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.
GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.
Bristol-Myers Squibb shares fell as a failed cancer-drug trial at AstraZeneca could have negative implications for its similar immunotherapy treatment regimen.
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma
While reporting strong earnings, New Haven, Conn.-based Alexion Pharmaceuticals also indicated the company plans to retool its research-and-development strategy.
AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares.
GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.
Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.
Ironwood Pharmaceuticals touted its Phase IIb drug candidate IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease (GERD), but investors seem wary as share prices were down more than 7 percent.
Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.